Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.
Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, Aso M, Kikuchi H, Nakamura A, Sekikawa M, Yoshiike F, Kitamura Y, Kimura N, Hachiya T, Tsurumi K, Agatsuma T, Megumi F, Nakamura K, Jingu D, Yamamoto H, Kosaka M, Yokouchi H. Tateishi K, et al. Among authors: jingu d. Jpn J Clin Oncol. 2024 Dec 4:hyae168. doi: 10.1093/jjco/hyae168. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39656678
Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma.
Inomata M, Kawashima Y, Saito R, Morinaga D, Nogawa H, Sato M, Suzuki Y, Yanagisawa S, Kikuchi T, Jingu D, Yoshimura N, Harada T, Miyauchi E. Inomata M, et al. Among authors: jingu d. Cancer Diagn Progn. 2024 Jul 3;4(4):515-520. doi: 10.21873/cdp.10357. eCollection 2024 Jul-Aug. Cancer Diagn Progn. 2024. PMID: 38962552 Free PMC article.
A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202.
Inomata M, Kawashima Y, Saito R, Morinaga D, Nogawa H, Sato M, Suzuki Y, Yanagisawa S, Kikuchi T, Jingu D, Yoshimura N, Harada T, Miyauchi E. Inomata M, et al. Among authors: jingu d. Oncol Lett. 2023 Jun 20;26(2):334. doi: 10.3892/ol.2023.13920. eCollection 2023 Aug. Oncol Lett. 2023. PMID: 37427337 Free PMC article.
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data.
Terai H, Soejima K, Shimokawa A, Horinouchi H, Shimizu J, Hase T, Kanemaru R, Watanabe K, Ninomiya K, Aragane N, Yanagitani N, Sakata Y, Seike M, Fujimoto D, Kasajima M, Kubo A, Kusumoto S, Oyamada Y, Fujiwara K, Mori M, Hashimoto M, Shingyoji M, Kodani M, Sakamoto J, Agatsuma T, Kashiwabara K, Inomata M, Tachihara M, Tanaka K, Hayashihara K, Koyama N, Matsui K, Minato K, Jingu D, Sakashita H, Hara S, Naito T, Okada A, Tanahashi M, Sato Y, Asano K, Takeda T, Nakazawa K, Harada T, Shibata K, Kato T, Miyaoka E, Yoshino I, Gemma A, Mitsudomi T. Terai H, et al. Among authors: jingu d. JTO Clin Res Rep. 2022 Sep 1;3(11):100404. doi: 10.1016/j.jtocrr.2022.100404. eCollection 2022 Nov. JTO Clin Res Rep. 2022. PMID: 36275911 Free PMC article.
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042).
Minegishi Y, Akagami T, Arai M, Saito R, Arai D, Murase K, Miura K, Watanabe S, Sakashita H, Miyabayashi T, Honda R, Jingu D, Hotta T, Isobe K, Nakazawa K, Ito K, Takamura K, Inomata M, Harada T, Sakakibara R, Nakagawa T, Shibuya H, Takenaka K, Kobayashi K, Seike M. Minegishi Y, et al. Among authors: jingu d. Lung Cancer. 2022 Oct;172:1-8. doi: 10.1016/j.lungcan.2022.07.009. Epub 2022 Jul 26. Lung Cancer. 2022. PMID: 35952438 Review.
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Oizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: jingu d. Int J Clin Oncol. 2022 Apr;27(4):823-824. doi: 10.1007/s10147-022-02118-8. Int J Clin Oncol. 2022. PMID: 35257278 Free PMC article. No abstract available.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: jingu d. Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub 2021 Oct 13. Int J Clin Oncol. 2022. PMID: 34643820 Free PMC article. Clinical Trial.
18 results